On September 18, 2020, the process of Korea Dasan Pharmaceutical Co., Ltd. investing in Shenyang Dasan Pharmaceutical Technology Co., Ltd. to establish a joint venture was substantially completed.

The joint venture will continue to uphold the corporate philosophy of "pursuing excellence," providing domestic and international clients with full-industry-chain, one-stop services covering chemistry-pharmacy-medicine, R&D-clinical-registration.

The joint venture will introduce Korea Dasan's advanced drug delivery technologies, leveraging its existing taste-masking technology development platform, poorly soluble drug microencapsulation technology development platform, and sustained/controlled-release pellet technology development platform. It is committed to developing pediatric drugs, geriatric drugs, and novel sustained and controlled-release formulations. Additionally, it has established a drug synthesis process development laboratory in the Shanghai International Medical Park. The company has assembled a team of top-tier domestic R&D project groups, supported by an experienced registration team and a comprehensive SOP system, enabling it to provide a full range of drug development services to domestic and international clients.